Eris Lifesciences files SEBI Regulation 74(5) certificate for Q1 FY27
Eris Lifesciences Limited has submitted its quarterly confirmation certificate under SEBI Regulation 74(5) for the period ending June 30, 2026. The certificate was issued by the company's RTA, MUFG Intime India Private Limited, confirming the processing of dematerialised securities.
This is a standard regulatory compliance filing that is expected from listed companies on a quarterly basis. It does not contain any new material information that would impact the company's operations or stock.
The announcement is a routine regulatory filing and does not contain any financial performance data or strategic updates that would indicate a positive or negative sentiment.
Eris Lifesciences Limited has submitted a confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026. This certificate was received from M/s. MUFG Intime India Private Limited, the company's Registrar and Share Transfer Agent (RTA).
The RTA confirmed that the securities received from depository participants for dematerialisation during the quarter were processed and listed on the stock exchanges. They also confirmed that the security certificates received were either accepted or rejected, and those accepted were mutilated and cancelled after verification, with the depositories' names substituted in the register of members within the prescribed timelines.
The company has duly confirmed and certified this information and is providing it for the information and records of the stock exchanges and depositories.
What to do with a filing like this
Eris Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Eris Lifesciences Limited. Read the original for the full detail.